GSK 650394 FUNDAMENTALS EXPLAINED

Oral HDAC inhibitor tucidinostat in individuals with relapsed or refractory peripheral T-cell lymphoma: phase IIb benefitsMany ongoing clinical investigations study tucidinostat use in various mixtures for relapsed and newly diagnosed PTCL (Tables three–5), showing that tucidinostat can generate synergistic results with other drugs.Olsen EA, Whit